China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.
CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the first quarter of 2025, showing an increase in revenue to RMB 535.88 million compared to the previous year. Despite the revenue growth, net profit decreased to RMB 139.29 million, and there was a significant net decrease in cash and cash equivalents, indicating potential liquidity challenges.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on bio-pharmaceutical products through its subsidiary CR Boya Bio-pharmaceutical. The company is involved in the development and distribution of pharmaceutical products and holds a significant share in CR Boya Bio-pharmaceutical, which is listed on the Shenzhen Stock Exchange.
YTD Price Performance: -19.85%
Average Trading Volume: 1,550
Technical Sentiment Signal: Buy
Current Market Cap: €3.56B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.